Home › Immunoglobulin Light-chain Amyloidosis › Minnesota › Rochester
Immunoglobulin Light-chain Amyloidosis clinical trials in Rochester, MN
5 studies for Immunoglobulin Light-chain Amyloidosis are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
RecruitingPhase 2
- GSK Investigational Site, Rochester
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
- Research Site, Rochester
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RecruitingPhase 3
- Mayo Clinic in Rochester, Rochester
Immunoglobulin Light-chain Amyloidosis trials in other cities
- Boston, MA7 studies
- New York City, NY4 studies
- Durham, NC4 studies
- Cleveland, OH3 studies
- Columbus, OH3 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer37 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Multiple Myeloma24 studies
- Heart Failure22 studies
- Prostate Cancer22 studies
- Pancreatic Cancer22 studies
- Endometrial Cancer20 studies
- Lung Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.